Contact
Please use this form to send email to PR contact of this press release:
OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension
TO:
Sara Gao
OWP PHARMACEUTICALS